Stoke Therapeutics, Inc. (STOK): Total Liabilities
$65.98M
As of 2025-12-31
$48.42M
As of 2026-06-30
-2.5%
3-year compound annual growth
+41.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $65.98M | +55.1% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $42.53M | -38.2% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $68.78M | -3.4% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $71.22M | +237.7% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $21.09M | +78.0% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $11.85M | +174.1% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $4.32M | +74.9% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $2.47M | n/a | 2020-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $65.98M | +55.1% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $397.87M | -7.7% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $28.52M | -23.6% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $262.35M | -13.0% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $697.32M | +10.4% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $465.08M | +6.5% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $211.49M | +6.2% |
| Liquidia Corp (LQDA) | 2025-12-31 | $283.19M | +87.6% |
Compare STOK, MRVI, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗